Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
81.84(c) 81.46(c) 81.74(c) 81.94(c) 81.88 Last
3 459 929 3 528 865 3 536 102 4 419 942 13 191 697 Volume
-0.56% -0.46% +0.34% +0.24% -0.07% Change
More quotes
Financials (USD)
Sales 2018 52 459 M
EBIT 2018 12 888 M
Net income 2018 11 683 M
Debt 2018 14 565 M
Yield 2018 3,46%
Sales 2019 53 782 M
EBIT 2019 13 861 M
Net income 2019 9 248 M
Debt 2019 11 722 M
Yield 2019 3,58%
P/E ratio 2018 14,72
P/E ratio 2019 20,91
EV / Sales2018 4,40x
EV / Sales2019 4,24x
Capitalization 216 B
More Financials
Company
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products.It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate.The Innovative Medicines segment researches, develops, manufactures, distributes and... 
Sector
Pharmaceuticals
Calendar
09/26Presentation
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
05:00pEMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
04:42pNOVARTIS : uBiome moving into therapeutics with $83M series C
AQ
02:30pTriple Set of EMA Recommendations for Novartis Drugs
DJ
01:28pNOVARTIS : Sandoz receives positive CHMP opinion for proposed biosimilar pegfilg..
GL
01:26pNOVARTIS : receives positive CHMP opinion for Gilenya® for the treatment of chil..
GL
01:25pNOVARTIS : announces positive CHMP opinion for one-time gene therapy Luxturna® t..
GL
10:26aAMICUS THERAPEUTICS : Celenex takeout first of several planned gene therapy deal..
AQ
09/20NOVARTIS : announces NEJM publication of landmark PARADIGMS study demonstrating ..
AQ
09/20NOVARTIS : Patent Issued for Devices, Systems, And Methods For Visualization Of ..
AQ
09/20NOVARTIS : "Methods And Compositions For Determining The Potency Of A Therapeuti..
AQ
More news
Sector news : Pharmaceuticals - NEC
05:00pEMA Nod to Eli Lilly Drug Stokes Competition in Migraine Prevention Market
DJ
02:23pGlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
DJ
02:18pELI LILLY AND : Gets Positive CHMP Opinion for Migraine Drug Emgality
DJ
02:04pAbbVie Gets Positive CHMP Opinion for Combination of Venclyxto With Rituximab..
DJ
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on NOVARTIS 
NOVARTIS - 09/03
Technically solid
BUY
NOVARTIS - 04/30
Underpinned by a support level
BUY
More Strategies
Latest Tweets
03:59pWhy former Novartis CEO Joe Jimenez joined a microbiome startup's board  
03:50pNovartis drums up EU launch plans as CHMP gives thumbs up to Spark’s gene the..
1
03:43pEx-Novartis Chief Joins uBiome to Help Launch Discovery and Development Busin..
1
03:29pPharmalot.. Pharmalittle.. Good Morning.. Novartis employees brace for layoff.. 
02:30pTriple Set of EMA Recommendations for Novartis Drugs  
More tweets
Qtime:181
News from SeekingAlpha
10:07aNew opinions from EMA advisor CHMP 
10:02aYOUR DAILY SCOOP : Unum's Positive Data, Theravance's Treatment Benefit, Collect.. 
08:00aBreaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is I.. 
09/19Almirall's tildrakizumab OK'd in Europe for plaque psoriasis 
09/19Novartis down 1% premarket on NICE rejection of Kymriah for adults 
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 91,5 $
Spread / Average Target 7,0%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-0.56%216 108
JOHNSON & JOHNSON0.53%380 898
PFIZER19.44%256 467
ROCHE HOLDING LTD.-4.65%210 186
MERCK AND COMPANY25.79%188 241
AMGEN17.99%132 756